

CORTEX PHARMACEUTICALS INC/DE/  
Form 8-K  
October 12, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

October 11, 2007

---

**CORTEX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-16467**  
(Commission File Number)

**33-0303583**  
(I.R.S Employer  
Identification No.)

**15241 Barranca Parkway**  
**Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**Registrant's telephone number, including area code: (949) 727-3157**

N/A

(Former name or former address, if changed since last report.)

---

## Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

On October 11, 2007, Cortex Pharmaceuticals, Inc. (the Company) issued a press release announcing that, on October 10, 2007, the United States Food and Drug Administration (the FDA) informed the Company that the FDA would soon be sending formal notice that it would not approve the Company's Investigational New Drug Application for a Phase IIb study of CX717 in attention deficit hyperactivity disorder. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<i>Exhibit Number</i>	<i>Description</i>
99.1	Press release of Cortex Pharmaceuticals, Inc., dated October 11, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEX PHARMACEUTICALS, INC.

Date: October 12, 2007

By: /s/ Maria S. Messinger  
Maria S. Messinger  
Vice President, Chief Financial Officer and Corporate Secretary

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequential</b>	<b>Page No.</b>
99.1	Press release of Cortex Pharmaceuticals, Inc., dated October 11, 2007.		5